## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.2% below STRENGTH zone (4.0-10.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. New surgery guidelines expand use of vacuum dressings to protect incisions**
- Source: Stock Titan | 20251217T210944 | Somewhat-Bullish | Relevance: 100%
- Solventum announced new international consensus recommendations for the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings. Published in the International Wound Journal, these guidelines, based on a meta-analysis of 84 studies, expand ciNPT's use to high-risk patients and complex incisions, aiming to reduce surgical site complications. Solventum's Prevena™ Therapy is highlighted as the only ciNPT system incorporating ROCF dressings.

**2. Solventum Corporation reflects on transformative year**
- Source: MSN | 20251217T100824 | Somewhat-Bullish | Relevance: 100%
- Solventum Corporation reflects on a transformative year. The article details key changes or events that have shaped the company's performance and outlook over the past year.

**3. Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength**
- Source: Finviz | 20251216T160500 | Bullish | Relevance: 100%
- Solventum announced it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare. This validation confirms Solventum's MedSurg segment can consistently deliver critical healthcare products, ensuring uninterrupted patient care even during supply disruptions. The achievement reflects Solventum's significant investment in visibility tools, risk management, and contingency planning since its inception.

**4. Solventum Corp Reflects on Year of Growth and Transformation**
- Source: TradingView — Track All Markets | 20251216T140834 | Bullish | Relevance: 100%
- Solventum Corp has highlighted its significant progress during its first year as a standalone public company. The company launched a long-range plan, sold a segment to optimize its portfolio, achieved six consecutive quarters of positive volume growth, initiated a $1 billion share repurchase program, and announced an acquisition to expand its offerings. This information is based on an SEC filing from December 16, 2025.

**5. Is Solventum Stock Outperforming the Nasdaq?**
- Source: inkl | 20251216T100834 | Bullish | Relevance: 100%
- Solventum Corporation (SOLV), a large-cap healthcare company, has shown strong performance, outpacing the Nasdaq Composite (NASX) over the past three months, 52 weeks, and year-to-date. The company's recent acquisition of Acera Surgical is expected to further strengthen its advanced wound care portfolio. Analysts maintain a "Moderate Buy" rating for SOLV, with a mean price target suggesting a 5.1% upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Forward P/E 12.7x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 12.7 |
| Current P/E | 13.4 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.5% to -2.2% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.83), momentum weakening. RSI neutral at 51. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.24% (CS: 20) | Weak |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | -0.83 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.69
- **Stop Loss:** $76.85 (4.8% risk)
- **Target:** $84.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $19,930.43
- **Portfolio %:** 19.93%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*